Hinova Pharmaceuticals (SH:688302) 智通财经网·2025-11-24 09:21Core Viewpoint - Haichuang Pharmaceutical (688302.SH) has received approval from the National Medical Products Administration of China for clinical trials of HP518 tablets in combination with anti-tumor drugs for the treatment of advanced prostate cancer, marking a significant step in the development of innovative cancer therapies [1] Company Summary - HP518 tablets have been approved for clinical trials in China, Australia, and the United States for advanced prostate cancer, with no similar products currently approved for market [1] - The drug is composed of a target protein ligand, an E3 ligase ligand, and a linker, which induces the ubiquitination of the androgen receptor (AR) and relies on proteasomal degradation to deeply inhibit the AR signaling pathway, achieving anti-tumor effects [1] - As a novel PROTAC oral drug, HP518 has shown high degradation activity against both resistant AR mutants and wild-type AR proteins in preclinical studies, demonstrating excellent anti-cancer activity against AR-dependent prostate cancer cells [1] Industry Summary - The approval of HP518 tablets represents a potential breakthrough in addressing treatment resistance caused by mutations in prostate cancer, providing new therapeutic options for patients [1]